Out-Coaching the Competition

How Biohaven Pharma Turned Manager Leverage into a $12B Exit

In 2019, Biohaven Pharma was an underdog. By 2022, it was acquired by Pfizer for $12 billion. The turning point? A bold decision to coach first-line managers, not reps.

Out-Coaching the Competition: How Biohaven Pharma Turned Manager Leverage Into a $12B Exit reveals how a focus on first-line manager development drove execution, resilience, and market share.

Inside this case study, you'll learn how:

How data exposed performance blind spots
The playbook for scaling execution through first-line managers
What great coaching actually looks like

This isn’t just a success story. It’s a strategy.

Download the Case Study